Result of AGM
Scancell Holdings PLC announced that all resolutions proposed at the Annual General Meeting held on October 30, 2025, were duly passed. The company is focused on developing targeted off-the-shelf active immunotherapies. Their lead product from the DNA ImmunoBody platform, iSCIB1+, has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy and additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the lead peptide immunotherapy from their Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. Additionally, GlyMab Therapeutics Ltd., a wholly-owned subsidiary, has an early-stage pipeline of GlyMab antibodies, two of which have been licensed and are being developed by Genmab A/S.
Select text to share a quote on X · sign in to keep highlights & notes in your SCLP notes
Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies to treat cancer, announces that all resolutions proposed at the Annual General Meeting held today were duly passed.
Scancell (LSE:SCLP; www.scancell.co.uk) is a clinical stage biotechnology company developing targeted off-the-shelf active immunotherapies, to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, the lead product from their DNA ImmunoBody® platform has demonstrated safe, durable and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the lead peptide immunotherapy from their Moditope® platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, Scancell's wholly owned subsidiary, GlyMab Therapeutics Ltd., has been established with the intention to hold and develop an exciting early-stage pipeline of high affinity GlyMab® antibodies targeting tumour specific glycans, two of which already have been licensed and are being developed by Genmab A/S, an international biotechnology company and global leader in the antibody therapeutics space.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.